文献速递临床试验与 GCP流行病学与生物统计

临床试验中孕妇的公平纳入:科学与伦理整合路径

Fair inclusion of pregnant women in clinical trials: an integrated scientific and ethical approach.
PubMed 文献 · Trials · 2018-01-29

本文通过概念性伦理与方法学分析,探讨孕妇研究纳入的公平性及排除的科学理由,提出公平纳入意味着不因怀孕而排除合格孕妇并优先关注其研究利益,并主张在证据不足时推动孕妇专门试验及早期纳入。

要点

  • 公平纳入要求合格孕妇不因怀孕被排除,且其研究利益应获实质优先关注。
  • 若已知或假定干预效应在孕妇与非孕妇间存在差异或无差异,孕妇专门试验可能更可取。
  • 无差异证据时可考虑上市后研究或登记库;无定论且不太可能大差异或完全等价时纳入孕妇应充分。

核心结论

  • 公平纳入孕妇意味着应推动孕妇专门试验,并在研究过程最早阶段实现纳入。
  • 研究者、伦理委员会、科学顾问委员会、资助方、药品监管机构、制药公司、期刊编辑等有共同责任发展孕妇用药证据基础。

研究设计与样本

  • 概念性伦理与方法学分析与评价,主题为公平纳入。

主要发现

  • 公平纳入孕妇包括合格孕妇不单纯因怀孕被排除,以及孕妇研究利益被优先关注。
  • 仅纳入少数孕妇于全女性人群无助于确定治疗在孕妇中的有效性和安全性。
  • 若假定或已知干预效应在孕妇与其他亚群间存在差异或无差异,孕妇专门试验可能更可取。
  • 无差异时可优先开展上市后研究或建立登记库;无定论且不太可能大差异或完全等价时,纳入孕妇应充分,取决于研究问题可体现为孕妇与非孕妇比例的代表性或对孕妇过度抽样。

临床怎么用

  • 根据研究问题,在无差异或等价证据不足且不太可能大差异或完全等价时,应确保孕妇纳入充分,可表现为比例代表性或对孕妇过度抽样。
  • 在假定或已知效应存在差异或无差异时,可优先考虑孕妇专门试验;无差异时也可考虑上市后研究或登记库。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since pregnant women are severely underrepresented in clinical research, many take the position that the exclusion of pregnant women from research must be justified unless there are compelling "scientific reasons" for their exclusion. However, it is questionable whether this approach renders research with pregnant women fair. This paper analyzes and evaluates when research with pregnant women can be considered as fair and what constitutes scientific reasons for exclusion. METHODS: Conceptual ethical and methodological analysis and evaluation of fair inclusion. RESULTS: Fair inclusion of pregnant women means (1) that pregnant women who are eligible are not excluded solely for being pregnant and (2) that the research interests of pregnant women are prioritized, meaning that they ought to receive substantially more attention. Fairness does not imply that pregnant women should be included in virtually every research project, as including only a few pregnant women in a population consisting only of women will not help to determine the effectiveness and safety of a treatment in pregnant women. Separate trials in pregnant women may be preferable once we assume, or know, that effects of interventions in pregnant women differ from the effects in other subpopulations, or when we assume, or know, that there are no differences. In the latter case, it may be preferable to conduct post-marketing studies or establish registries. If there is no conclusive evidence indicating either differences or equivalence of effects between pregnant and non-pregnant women, yet it seems unlikely that major differences or exact equivalence exist, the inclusion of pregnant women should be sufficient. Depending on the research question, this boils down to representativeness in terms of the proportion of pregnant and non-pregnant women, or to oversampling pregnant women. CONCLUSIONS: Fair inclusion of pregnant women in research implies that separate trials in pregnant women should be promoted. Inclusion of pregnant women has to be realized at the earliest phases of the research process. In addition to researchers and research ethics committees, scientific advisory councils, funders, drug regulatory agencies, pharmaceutical companies, journal editors and others have a joint responsibility to further develop the evidence base for drug use in pregnant women.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. van der Graaf R, van der Zande ISE, den Ruijter HM, et al. Fair inclusion of pregnant women in clinical trials: an integrated scientific and ethical approach. Trials. 2018. PMID: 29378652. doi:10.1186/s13063-017-2402-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。